As Drug Expenditure Rationalization Plan has been implemented in Korea in 2006, pharmacoeconomics (PE) guideline was developed by Health Insurance Review and Assessment service (HIRA) to appraise the economic evaluation. Since the implementation of HIRA PE guideline, various necessities have arisen by the viewers on how to practically interpret and use the guideline. OBJECTIVES: This survey was conducted to consolidate opinions of KRPIA (Korean Research-based Pharmaceutical Industry Association) and KPMA (Korea Pharmaceutical Manufacturers Association) on the main issues of the revision of HIRA PE guideline for new medicine. METHODS: The survey protocol was developed based on the experience of new drug listing by KRPIA and KPMA members and completed during May 2011 by e-mails in writing. The key anticipated outcomes were which categories of the guideline revision the member companies consider necessary RESULTS: Among KRPIA and KPMA member companies, 19 companies had answered. 63% (n=12) of the subjects answered they could not select the analysis method between CEA and CUA because HIRA does not appreciate their choices. Among 89% (n=17) those who selected to answer the questions regarding detailed guideline for utility study, 71% (n=12) responded they agree with the necessity of the guideline on the condition if CUA is not applicable CEA could be appreciated. Meanwhile, 26% (n=5) responded they had investigated clinical specialist or patient groups to design and conduct effectiveness or utility analysis and the most frequently used method was a question survey followed by Delphi panel and focus interview. CONCLUSIONS: The member companies have demands for the revision in the way of operating the economic evaluation. The key demands are creation of the manual to be followed for the conduct of economic evaluation study, flexibility of the operation in the consideration of severity of the indication, efficient and transparent management of the consultation.